LUCAR-G39P is positioned in the competitive landscape of CAR-T therapies, specifically targeting relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Given the increasing prevalence of NHL and the limitations of existing therapies, this dual-targeted approach may enhance efficacy and reduce relapse rates. The trial's termination after achieving proof of concept suggests potential for further development, possibly leading to a Phase II study. Collaboration with Nanjing Legend Biotech Co. indicates strategic partnerships that may enhance market access and resource allocation. The asset's success could capture a significant share of the CAR-T market, which is projected to grow substantially in the coming years.